ArticleCancer2013
Impact of race and ethnicity on features and outcome of ductal carcinoma in situ of the breast.
Article in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Utilisation of endocrine therapy for cancer in Indigenous peoples: a systematic review and meta-analysis.BMC cancer · 2024Pooled it
- Racial and Ethnic Disparities in Outcomes After Breast-Conserving Therapy and Endocrine Therapy for DCIS: A Post-Hoc Analysis of the NSABP B-35 Randomized Clinical Trial.Annals of surgical oncology · 2023Trial
- Investigating the effectiveness of adjuvant therapy for patients with hormone receptor-positive ductal carcinoma in situ.PloS one · 2022Trial
- Racial Disparity in Ductal Carcinoma in Situ: Risk-Predictive and Actionable Biomarkers for Early Intervention.Cancers · 2026Review
- Risk factors for ductal carcinoma in situ: comparisons with invasive breast cancer.Breast cancer research : BCR · 2026Article
- Endocrine therapy initiation among women diagnosed with ductal carcinoma in situ from 2001 to 2018.Breast cancer research and treatment · 2024Article
- Overcoming Barriers in Ductal Carcinoma In Situ Management: From Overtreatment to Optimal Treatment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Breast cancer in Trinidad and Tobago: Etiopathogenesis, histopathology and receptor study.Journal of family medicine and primary care · 2021Article
- Identifying the link between chemical exposures and breast cancer in African American women via integrated in vitro and exposure biomarker data.Toxicology · 2021Article
- Metastatic and triple-negative breast cancer: challenges and treatment options.Drug delivery and translational research · 2018Review
- Comparing treatment and outcomes of ductal carcinoma in situ among women in Missouri by race.Breast cancer research and treatment · 2016Article
- Epidemiological risk factors associated with inflammatory breast cancer subtypes.Cancer causes & control : CCC · 2016Article
- Tamoxifen Initiation After Ductal Carcinoma In Situ.The oncologist · 2016Article
- Racial disparities in risk of second breast tumors after ductal carcinoma in situ.Breast cancer research and treatment · 2014Article
- Long-term risk perceptions of women with ductal carcinoma in situ.The oncologist · 2013Article
- The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States-part 3: Hispanic-American patients.Advances in radiation oncologyArticle
- The pervasive crisis of diminishing radiation therapy access for vulnerable populations in the United States, part 1: African-American patients.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe impact of race and ethnicity on the biologic features and outcome variables of women who are diagnosed with preinvasive breast cancer-ductal carcinoma in situ (DCIS)-has not been addressed widely in the published literature.
methodsPatient demographic, clinical, and pathologic features and outcome variables were analyzed with respect to the patient's initial self-reported race/ethnicity among women who received treatment for a diagnosis of pure DCIS from 1996 to 2009.
resultsOf 1902 patients, 1411 were white (74.2%), 214 were African American (11.3%), 175 were Hispanic (9.1%), and 102 were Asian/Pacific Islander (5.4%). The majority of patients were between ages 41 and 70 years (83%). Patients of Hispanic and Asian/Pacific Islander descent were significantly younger than white and African American patients (P < .001). DCIS size and grade, the presence of necrosis, and the frequency of breast-conserving surgery did not differ significantly between groups. African American patients aged >70 years and Hispanic patients aged <50 years were significantly more likely to have estrogen receptor-positive DCIS than patients of other races in the same age categories (P < .001). Adjuvant radiotherapy and tamoxifen were received significantly less often by white women (P < .001). At a median follow-up of 4.8 years (range, 1-14 years), recurrence rates and the development of contralateral breast cancer did not differ significantly among racial/ethnic groups when stratified by treatments received.
conclusionsThere was variation in age at presentation, biologic features, and treatment of DCIS among the different ethnic groups. Additional studies with larger numbers of ethnic minority patients are needed to confirm whether the consistent application of evidence-based treatment practices presents an opportunity for reducing disparities in patients with DCIS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.